AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML. However, accelera...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisberg, E, Manley, P, Mestan, J, Cowan-Jacob, S, Ray, A, Griffin, J D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361347/
https://www.ncbi.nlm.nih.gov/pubmed/16721371
http://dx.doi.org/10.1038/sj.bjc.6603170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361347/
https://www.ncbi.nlm.nih.gov/pubmed/16721371
http://dx.doi.org/10.1038/sj.bjc.6603170

Ejemplares similares